Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
MELBOURNE, Australia, July 28, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease provides its cashflow results for the quarter ended June 30, 2022 (Q4 FY22). Financial Highlights: Cash receipts of A$3.5 million, including the R&D tax incentive receipt of A$1.4 million up 43% from prior quarter, with cash balances of A$11.7 million as at June 30, 2022Revenue from custom
MELBOURNE, Australia, July 18, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that we are partnering with Melbourne based Siles Health, a leading Obstetrics and Gynaecology practice, to implement geneType Multi-Risk Test as part of their commitment to remain at the forefront of contemporary personalised patient health care. Siles Health, fou
MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce that it has completed the acquisition of the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA as announced on May 16, 20221. Acquisition Highlights: Strategic acquisition strengthens the direct-to-consumer channel for GENE,
MELBOURNE, Australia, July 05, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company’s recently acquired, EasyDNA, has embarked on a significant expansion in both its test portfolio and geographical reach. Highlights: Carrier Testing and Non-Invasive Prenatal Tests (NIPT) available to our European marketIndia team has partnered with stu
MELBOURNE, Australia, July 01, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the Company has commenced initial implementation of its geneType Risk Assessment Test at 16 medical practices across the East Coast of Australia. GeneType Hub strategy focuses on establishing centers of excellence and the routine use of geneType Risk Assessment Tes
MELBOURNE, Australia, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the completion of an independently developed and validated customizable Budget Impact Model (BIM), which demonstrates significant health and economic benefits directly attributed to the implementation of geneType Breast Cancer Risk Assessment Test. Breast cancer ri
MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor
MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re